Tzu Chi University

AIM: The impact of the original International Children's Continence Society (ICCS) terminology document on lower urinary tract (LUT) function resulted in the global establishment of uniformity and clarity in the characterization of LUT function and dysfunction in children across multiple healthcare disciplines. The present document serves as a stand-alone terminology update reflecting refinement and current advancement of knowledge on pediatric LUT function. METHODS: A variety of worldwide experts from multiple disciplines within the ICCS leadership who care for children with LUT dysfunction were assembled as part of the standardization committee. A critical review of the previous ICCS terminology document and the current literature was performed. Additionally, contributions and feedback from the multidisciplinary ICCS membership were solicited. RESULTS: Following a review of the literature over the last 7 years, the ICCS experts assembled a new terminology document reflecting current understanding of bladder function and LUT dysfunction in children using the resources from the literature review, expert opinion and ICCS member feedback. CONCLUSIONS: The present ICCS terminology document provides a current and consensus update to the evolving terminology and understanding of LUT function in children. Neurourol. Urodynam. 35:471-481, 2016. © 2015 Wiley Periodicals, Inc.

Ischemia-reperfusion injury is associated with serious clinical manifestations, including myocardial hibernation, acute heart failure, cerebral dysfunction, gastrointestinal dysfunction, systemic inflammatory response syndrome, and multiple organ dysfunction syndrome. Ischemia-reperfusion injury is a critical medical condition that poses an important therapeutic challenge for physicians. In this review article, we present recent advances focusing on the basic pathophysiology of ischemia-reperfusion injury, especially the involvement of reactive oxygen species and cell death pathways. The involvement of the NADPH oxidase system, nitric oxide synthase system, and xanthine oxidase system are also described. When the blood supply is re-established after prolonged ischemia, local inflammation and ROS production increase, leading to secondary injury. Cell damage induced by prolonged ischemia-reperfusion injury may lead to apoptosis, autophagy, necrosis, and necroptosis. We highlight the latest mechanistic insights into reperfusion-injury-induced cell death via these different processes. The interlinked signaling pathways of cell death could offer new targets for therapeutic approaches. Treatment approaches for ischemia-reperfusion injury are also reviewed. We believe that understanding the pathophysiology ischemia-reperfusion injury will enable the development of novel treatment interventions.

BACKGROUND: The presence of hepatitis B e antigen (HBeAg) in serum indicates active viral replication in hepatocytes. HBeAg is thus a surrogate marker for the presence of hepatitis B virus DNA. We conducted a prospective study to determine the relation between positivity for hepatitis B surface antigen (HBsAg) and HBeAg and the development of hepatocellular carcinoma. METHODS: In 1991 and 1992, we enrolled 11,893 men without evidence of hepatocellular carcinoma (age range, 30 to 65 years) from seven townships in Taiwan. Serum samples obtained at the time of enrollment were tested for HBsAg and HBeAg by radioimmunoassay. The diagnosis of hepatocellular carcinoma was ascertained through data linkage with the computerized National Cancer Registry in Taiwan and with death certificates. We performed a multiple regression analysis to determine the relative risk of hepatocellular carcinoma among men who were positive for HBsAg alone or for HBsAg and HBeAg, as compared with those who were negative for both. RESULTS: There were 111 cases of newly diagnosed hepatocellular carcinoma during 92,359 person-years of follow-up. The incidence rate of hepatocellular carcinoma was 1169 cases per 100,000 person-years among men who were positive for both HBsAg and HBeAg, 324 per 100,000 person-years for those who were positive for HBsAg only, and 39 per 100,000 person-years for those who were negative for both. After adjustment for age, sex, the presence or absence of antibodies against hepatitis C virus, cigarette-smoking status, and use or nonuse of alcohol, the relative risk of hepatocellular carcinoma was 9.6 (95 percent confidence interval, 6.0 to 15.2) among men who were positive for HBsAg alone and 60.2 (95 percent confidence interval, 35.5 to 102.1) among those who were positive for both HBsAg and HBeAg, as compared with men who were negative for both. CONCLUSIONS: Positivity for HBeAg is associated with an increased risk of hepatocellular carcinoma.

Stem cells have two features: the ability to differentiate along different lineages and the ability of self-renewal. Two major types of stem cells have been described, namely, embryonic stem cells and adult stem cells. Embryonic stem cells (ESC) are obtained from the inner cell mass of the blastocyst and are associated with tumorigenesis, and the use of human ESCs involves ethical and legal considerations. The use of adult mesenchymal stem cells is less problematic with regard to these issues. Mesenchymal stem cells (MSCs) are stromal cells that have the ability to self-renew and also exhibit multilineage differentiation. MSCs can be isolated from a variety of tissues, such as umbilical cord, endometrial polyps, menses blood, bone marrow, adipose tissue, etc. This is because the ease of harvest and quantity obtained make these sources most practical for experimental and possible clinical applications. Recently, MSCs have been found in new sources, such as menstrual blood and endometrium. There are likely more sources of MSCs waiting to be discovered, and MSCs may be a good candidate for future experimental or clinical applications. One of the major challenges is to elucidate the mechanisms of differentiation, mobilization, and homing of MSCs, which are highly complex. The multipotent properties of MSCs make them an attractive choice for possible development of clinical applications. Future studies should explore the role of MSCs in differentiation, transplantation, and immune response in various diseases.

Apoptosis or programmed cell death is natural way of removing aged cells from the body. Most of the anti-cancer therapies trigger apoptosis induction and related cell death networks to eliminate malignant cells. However, in cancer, de-regulated apoptotic signaling, particularly the activation of an anti-apoptotic systems, allows cancer cells to escape this program leading to uncontrolled proliferation resulting in tumor survival, therapeutic resistance and recurrence of cancer. This resistance is a complicated phenomenon that emanates from the interactions of various molecules and signaling pathways. In this comprehensive review we discuss the various factors contributing to apoptosis resistance in cancers. The key resistance targets that are discussed include (1) Bcl-2 and Mcl-1 proteins; (2) autophagy processes; (3) necrosis and necroptosis; (4) heat shock protein signaling; (5) the proteasome pathway; (6) epigenetic mechanisms; and (7) aberrant nuclear export signaling. The shortcomings of current therapeutic modalities are highlighted and a broad spectrum strategy using approaches including (a) gossypol; (b) epigallocatechin-3-gallate; (c) UMI-77 (d) triptolide and (e) selinexor that can be used to overcome cell death resistance is presented. This review provides a roadmap for the design of successful anti-cancer strategies that overcome resistance to apoptosis for better therapeutic outcome in patients with cancer.

BACKGROUND: Insulin resistance (IR) and the consequences of compensatory hyperinsulinemia are pathogenic factors for a set of metabolic abnormalities, which contribute to the development of diabetes mellitus and cardiovascular diseases. We compared traditional lipid levels and ratios and combined them with fasting plasma glucose (FPG) levels or adiposity status for determining their efficiency as independent risk factors for IR. METHODS: We enrolled 511 Taiwanese individuals for the analysis. The clinical usefulness of various parameters--such as traditional lipid levels and ratios; visceral adiposity indicators, visceral adiposity index (VAI), and lipid accumulation product (LAP); the product of triglyceride (TG) and FPG (the TyG index); TyG with adiposity status (TyG-body mass index [BMI]) and TyG-waist circumference index [WC]); and adipokine levels and ratios--was analyzed to identify IR. RESULTS: For all lipid ratios, the TG/high-density lipoprotein cholesterol (HDL-C) ratio had the highest additional percentage of variation in the homeostasis model assessment of insulin resistance (HOMA-IR; 7.0% in total); for all variables of interest, TyG-BMI and leptin-adiponectin ratio (LAR) were strongly associated with HOMA-IR, with 16.6% and 23.2% of variability, respectively. A logistic regression analysis revealed similar patterns. A receiver operating characteristic (ROC) curve analysis indicated that TG/HDL-C was a more efficient IR discriminator than other lipid variables or ratios. The area under the ROC curve (AUC) for VAI (0.734) and TyG (0.708) was larger than that for TG/HDL-C (0.707). TyG-BMI and LAR had the largest AUC (0.801 and 0.801, respectively). CONCLUSION: TyG-BMI is a simple, powerful, and clinically useful surrogate marker for early identification of IR.

The human umbilical cord is a promising source of mesenchymal stem cells (HUCMSCs). Unlike bone marrow stem cells, HUCMSCs have a painless collection procedure and faster self-renewal properties. Different derivation protocols may provide different amounts and populations of stem cells. Stem cell populations have also been reported in other compartments of the umbilical cord, such as the cord lining, perivascular tissue, and Wharton's jelly. HUCMSCs are noncontroversial sources compared to embryonic stem cells. They can differentiate into the three germ layers that promote tissue repair and modulate immune responses and anticancer properties. Thus, they are attractive autologous or allogenic agents for the treatment of malignant and nonmalignant solid and soft cancers. HUCMCs also can be the feeder layer for embryonic stem cells or other pluripotent stem cells. Regarding their therapeutic value, storage banking system and protocols should be established immediately. This review critically evaluates their therapeutic value, challenges, and future directions for their clinical applications.

BACKGROUND: The risk of hepatocellular carcinoma (HCC) increases with increasing level of hepatitis B virus (HBV) in serum (viral load). However, it is unclear whether genetic characteristics of HBV, including HBV genotype and specific genetic mutations, contribute to the risk of HCC. We examined the HCC risk associated with HBV genotypes and common variants in the precore and basal core promoter (BCP) regions. METHODS: From January 5, 1991, to December 21, 1992, baseline blood samples were collected from 2762 Taiwanese men and women who were seropositive for HBV surface antigen but had not been diagnosed with HCC; the samples were tested for HBV viral load by real-time polymerase chain reaction and genotyped by melting curve analysis. Participants who had a baseline serum HBV DNA level greater than 10(4) copies/mL (n = 1526) were tested for the precore G1896A and BCP A1762T/G1764A mutants by direct sequencing. Incident cases of HCC were ascertained through follow-up examinations and computerized linkage to the National Cancer Registry and death certification profiles. A Cox proportional hazards model was used to estimate the risk of HCC associated with HBV genotype and precore and BCP mutants after adjustment for other risk factors. All statistical tests were two-sided. RESULTS: A total of 153 HCC cases occurred during 33 847 person-years of follow-up. The HCC incidence rates per 100 000 person-years for participants infected with HBV genotype B or C were 305.6 (95% confidence interval [CI] = 236.9 to 388.1) and 785.8 (95% CI = 626.8 to 972.9), respectively. Among participants with a baseline HBV DNA level of at least 10(4) copies/mL, HCC incidence per 100 000 person-years was higher for those with the precore G1896 (wild-type) variant than for those with the G1896A variant (955.5 [95% CI = 749.0 to 1201.4] vs 269.4 [95% CI = 172.6 to 400.9]) and for those with the BCP A1762T/G1764A double mutant than for those with BCP A1762/G1764 (wild-type) variant (1149.2 [95% CI = 872.6 to 1485.6] vs 358.7 [95% CI = 255.1 to 490.4]). The multivariable-adjusted hazard ratio of developing HCC was 1.76 (95% CI = 1.19 to 2.61) for genotype C vs genotype B, 0.34 (95% CI = 0.21 to 0.57) for precore G1896A vs wild type, and 1.73 (95% CI = 1.13 to 2.67) for BCP A1762T/G1764A vs wild type. Risk was highest among participants infected with genotype C HBV and wild type for the precore 1896 variant and mutant for the BCP 1762/1764 variant (adjusted hazard ratio = 2.99, 95% CI = 1.57 to 5.70, P < .001). CONCLUSIONS: HBV genotype C and specific alleles of BCP and precore were associated with risk of HCC. These associations were independent of serum HBV DNA level.

To clarify the influence of gender on sympathetic and parasympathetic control of heart rate in middle-aged subjects and on the subsequent aging process, heart rate variability (HRV) was studied in normal populations of women (n = 598) and men (n = 472) ranging in age from 40 to 79 yr. These groups were divided into eight age strata at 5-yr intervals and were clinically diagnosed as having no hypertension, hypotension, diabetic neuropathy, or cardiac arrhythmia. Frequency-domain analysis of short-term, stationary R-R intervals was performed, which reveals very-low-frequency power (VLF; 0.003-0.04 Hz), low-frequency power (LF; 0.04-0.15 Hz), high-frequency power (HF; 0.15-0.40 Hz), the ratio of LF to HF (LF/HF), and LF and HF power in normalized units (LF% and HF%, respectively). The distribution of variance, VLF, LF, HF, and LF/HF exhibited acute skewness, which was adjusted by natural logarithmic transformation. Women had higher HF in the age strata from 40 to 49 yr, whereas men had higher LF% and LF/HF between 40 and 59 yr. No disparity in HRV measurements was found between the sexes in age strata >/=60 yr. Although absolute measurements of HRV (variance, VLF, LF, and HF) decreased linearly with age, no significant change in relative measurements (LF/HF, LF%, and HF%), especially in men, was detected until age 60 yr. We conclude that middle-aged women and men have a more dominant parasympathetic and sympathetic regulation of heart rate, respectively. The gender-related difference in parasympathetic regulation diminishes after age 50 yr, whereas a significant time delay for the disappearance of sympathetic dominance occurs in men.

CELLO2GO (http://cello.life.nctu.edu.tw/cello2go/) is a publicly available, web-based system for screening various properties of a targeted protein and its subcellular localization. Herein, we describe how this platform is used to obtain a brief or detailed gene ontology (GO)-type categories, including subcellular localization(s), for the queried proteins by combining the CELLO localization-predicting and BLAST homology-searching approaches. Given a query protein sequence, CELLO2GO uses BLAST to search for homologous sequences that are GO annotated in an in-house database derived from the UniProt KnowledgeBase database. At the same time, CELLO attempts predict at least one subcellular localization on the basis of the species in which the protein is found. When homologs for the query sequence have been identified, the number of terms found for each of their GO categories, i.e., cellular compartment, molecular function, and biological process, are summed and presented as pie charts representing possible functional annotations for the queried protein. Although the experimental subcellular localization of a protein may not be known, and thus not annotated, CELLO can confidentially suggest a subcellular localization. CELLO2GO should be a useful tool for research involving complex subcellular systems because it combines CELLO and BLAST into one platform and its output is easily manipulated such that the user-specific questions may be readily addressed.

Background & Aims: This study investigated whether obesity, diabetes, and other metabolic factors are independently associated with hepatocellular carcinoma (HCC), stratified by hepatitis B virus (HBV) and hepatitis C virus (HCV) serostatus, and explored the possible joint influence of obesity/diabetes and HBV/HCV infections on the risk of HCC. Methods: A total of 23,820 residents in Taiwan were recruited and followed up for 14 years. All analyses were stratified by hepatitis B surface antigen (HBsAg) and antibody to HCV (anti-HCV) at enrollment, and 218 subjects positive for both seromarkers were excluded. Incident HCC cases were identified via linkage to the national cancer registry. Multivariate-adjusted relative risk (RRa) and 95% confidence interval (95% CI) were estimated using Cox proportional hazards models. Results: Extreme obesity (body mass index ≥30 kg/m2) was independently associated with a 4-fold risk of HCC (RRa, 4.13; 95% CI, 1.38–12.4) among anti-HCV–seropositive subjects and a 2-fold risk (RRa, 2.36; 95% CI, 0.91–6.17) in persons without HBV and HCV infections, after controlling for other metabolic components, but not in HBsAg-seropositive subjects (RRa, 1.36; 95% CI, 0.64–2.89). Diabetes was associated with HCC in all 3 groups, with the highest risk in those with HCV infection (RRa, 3.52; 95% CI, 1.29–9.24) and lowest in HBV carriers (RRa, 2.27; 95% CI, 1.10–4.66). We found more than 100-fold increased risk in HBV or HCV carriers with both obesity and diabetes, indicating synergistic effects of metabolic factors and hepatitis. Conclusions: The finding that both obesity and diabetes are predictors of HCC risk, possibly differently depending on HBV and HCV infection status, may shed some light in preventing HCC. Background & Aims: This study investigated whether obesity, diabetes, and other metabolic factors are independently associated with hepatocellular carcinoma (HCC), stratified by hepatitis B virus (HBV) and hepatitis C virus (HCV) serostatus, and explored the possible joint influence of obesity/diabetes and HBV/HCV infections on the risk of HCC. Methods: A total of 23,820 residents in Taiwan were recruited and followed up for 14 years. All analyses were stratified by hepatitis B surface antigen (HBsAg) and antibody to HCV (anti-HCV) at enrollment, and 218 subjects positive for both seromarkers were excluded. Incident HCC cases were identified via linkage to the national cancer registry. Multivariate-adjusted relative risk (RRa) and 95% confidence interval (95% CI) were estimated using Cox proportional hazards models. Results: Extreme obesity (body mass index ≥30 kg/m2) was independently associated with a 4-fold risk of HCC (RRa, 4.13; 95% CI, 1.38–12.4) among anti-HCV–seropositive subjects and a 2-fold risk (RRa, 2.36; 95% CI, 0.91–6.17) in persons without HBV and HCV infections, after controlling for other metabolic components, but not in HBsAg-seropositive subjects (RRa, 1.36; 95% CI, 0.64–2.89). Diabetes was associated with HCC in all 3 groups, with the highest risk in those with HCV infection (RRa, 3.52; 95% CI, 1.29–9.24) and lowest in HBV carriers (RRa, 2.27; 95% CI, 1.10–4.66). We found more than 100-fold increased risk in HBV or HCV carriers with both obesity and diabetes, indicating synergistic effects of metabolic factors and hepatitis. Conclusions: The finding that both obesity and diabetes are predictors of HCC risk, possibly differently depending on HBV and HCV infection status, may shed some light in preventing HCC. See CME quiz on page 293. The incidence of liver cancer is increasing in several developed countries and would continue to increase for some decades.1Bosch F.X. Ribes J. Diaz M. et al.Primary liver cancer: worldwide incidence and trends.Gastroenterology. 2004; 127: S5-S16Abstract Full Text Full Text PDF PubMed Scopus (2139) Google Scholar The estimated attributable risk for the combined effects of hepatitis B and C viral infections accounts for more than 80% of liver cancer cases worldwide.1Bosch F.X. Ribes J. Diaz M. et al.Primary liver cancer: worldwide incidence and trends.Gastroenterology. 2004; 127: S5-S16Abstract Full Text Full Text PDF PubMed Scopus (2139) Google Scholar Obesity and diabetes have been found to be associated with an increased risk of hepatocellular carcinoma (HCC) in several epidemiologic studies.2Moller H. Mellemgaard A. Lindvig K. et al.Obesity and cancer risk: a Danish record-linkage study.Eur J Cancer. 1994; 30A: 344-350Abstract Full Text PDF PubMed Scopus (398) Google Scholar, 3Wolk A. Gridley G. Svensson M. et al.A prospective study of obesity and cancer risk (Sweden).Cancer Causes Control. 2001; 12: 13-21Crossref PubMed Scopus (506) Google Scholar, 4Rapp K. Schroeder J. Klenk J. et al.Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria.Br J Cancer. 2005; 93: 1062-1067Crossref PubMed Scopus (270) Google Scholar, 5Calle E.E. Rodriguez C. Walker-Thurmond K. et al.Overweight, obesity and mortality from cancer in a prospective studied cohort of US adults.N Engl J Med. 2003; 348: 1625-1638Crossref PubMed Scopus (5870) Google Scholar, 6Samanic C. Gridley G. Chow W.H. et al.Obesity and cancer risk among white and black United States veterans.Cancer Causes Control. 2004; 15: 35-43Crossref PubMed Scopus (263) Google Scholar, 7Nair S. Mason A. Eason J. et al.Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?.Hepatology. 2002; 36: 150-155Crossref PubMed Scopus (286) Google Scholar Five large population studies, 3 in Europe2Moller H. Mellemgaard A. Lindvig K. et al.Obesity and cancer risk: a Danish record-linkage study.Eur J Cancer. 1994; 30A: 344-350Abstract Full Text PDF PubMed Scopus (398) Google Scholar, 3Wolk A. Gridley G. Svensson M. et al.A prospective study of obesity and cancer risk (Sweden).Cancer Causes Control. 2001; 12: 13-21Crossref PubMed Scopus (506) Google Scholar, 4Rapp K. Schroeder J. Klenk J. et al.Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria.Br J Cancer. 2005; 93: 1062-1067Crossref PubMed Scopus (270) Google Scholar and 2 in the United States,5Calle E.E. Rodriguez C. Walker-Thurmond K. et al.Overweight, obesity and mortality from cancer in a prospective studied cohort of US adults.N Engl J Med. 2003; 348: 1625-1638Crossref PubMed Scopus (5870) Google Scholar, 6Samanic C. Gridley G. Chow W.H. et al.Obesity and cancer risk among white and black United States veterans.Cancer Causes Control. 2004; 15: 35-43Crossref PubMed Scopus (263) Google Scholar observed that obesity is associated with an increase in HCC incidence2Moller H. Mellemgaard A. Lindvig K. et al.Obesity and cancer risk: a Danish record-linkage study.Eur J Cancer. 1994; 30A: 344-350Abstract Full Text PDF PubMed Scopus (398) Google Scholar, 3Wolk A. Gridley G. Svensson M. et al.A prospective study of obesity and cancer risk (Sweden).Cancer Causes Control. 2001; 12: 13-21Crossref PubMed Scopus (506) Google Scholar, 4Rapp K. Schroeder J. Klenk J. et al.Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria.Br J Cancer. 2005; 93: 1062-1067Crossref PubMed Scopus (270) Google Scholar, 6Samanic C. Gridley G. Chow W.H. et al.Obesity and cancer risk among white and black United States veterans.Cancer Causes Control. 2004; 15: 35-43Crossref PubMed Scopus (263) Google Scholar and mortality,5Calle E.E. Rodriguez C. Walker-Thurmond K. et al.Overweight, obesity and mortality from cancer in a prospective studied cohort of US adults.N Engl J Med. 2003; 348: 1625-1638Crossref PubMed Scopus (5870) Google Scholar but a study conducted in an Asian country failed to obtain similar results.8Lai M.S. Hsieh M.S. Chiu Y.H. et al.Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection.Hepatology. 2006; 43: PubMed Scopus Google Scholar A of and cohort have diabetes to a 2-fold increased risk of M.S. Hsieh M.S. Chiu Y.H. et al.Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection.Hepatology. 2006; 43: PubMed Scopus Google Scholar, Chow W.H. et risk of liver cancer in with diabetes PubMed Scopus Google Scholar, Gridley G. et incidence in a cohort of with diabetes in PubMed Scopus Google Scholar, C. A. et and the risk of liver J Cancer. PubMed Scopus Google Scholar, H. et of diabetes in the of hepatocellular PubMed Scopus Google Scholar, The of diabetes in hepatocellular carcinoma: a study among United States J 2001; PubMed Google Scholar, Diabetes the risk of liver and hepatocellular 2004; Full Text Full Text PDF PubMed Scopus Google Scholar, et the risk of hepatocellular carcinoma in the United a population 2005; PubMed Scopus Google Scholar, et factors for hepatocellular carcinoma: of with viral hepatitis and diabetes 2002; 36: PubMed Scopus Google Scholar, H. et and cancer risk in and 2005; PubMed Scopus Google Scholar, E.E. et a of cancer mortality in a large cohort of US J 2004; PubMed Scopus Google Scholar, S. K. et of diabetes, and viral hepatitis on risk of hepatocellular carcinoma in and in the 2004; PubMed Scopus Google Scholar, M. M. et and the risk of cancer: from a cohort study in Med. 2006; PubMed Scopus Google Scholar, H. The diabetes and hepatocellular carcinoma: a of epidemiologic 2006; Full Text Full Text PDF PubMed Scopus Google Scholar large cohort study in M.S. Hsieh M.S. Chiu Y.H. et al.Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection.Hepatology. 2006; 43: PubMed Scopus Google Scholar studies, 3 M.S. Hsieh M.S. Chiu Y.H. et al.Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection.Hepatology. 2006; 43: PubMed Scopus Google Scholar, et the risk of hepatocellular carcinoma in the United a population 2005; PubMed Scopus Google Scholar, S. K. et of diabetes, and viral hepatitis on risk of hepatocellular carcinoma in and in the 2004; PubMed Scopus Google Scholar whether diabetes and HCC hepatitis infection status, but investigated the of a of hepatitis on the increasing prevalence of obesity and diabetes, is to the 2 factors other metabolic and and HCC hepatitis B and is a risk factor for is to whether metabolic factors are associated with HCC differently depending on hepatitis B virus (HBV) and hepatitis C virus (HCV) infection We conducted the using from a J. et of hepatocellular carcinoma a of hepatitis B virus 2006; PubMed Scopus Google Scholar, et B antigen and the risk of hepatocellular Engl J Med. 2002; PubMed Scopus Google Scholar, J. et risk on the of hepatitis B viral 2006; Full Text Full Text PDF PubMed Scopus Google Scholar that been followed up for more than in Taiwan and in cohort hepatitis B surface antigen (HBsAg) and antibody to HCV (anti-HCV) at We to whether obesity and diabetes other metabolic factors are independently associated with stratified by HBV and HCV to the possible joint influence of obesity/diabetes and HBV/HCV infections on the risk of HCC to the the in HCC risk is associated with is the study that the obesity/diabetes other metabolic factors and risk of HCC by and serostatus, the of HBV and HCV A of the and and was J. et of hepatocellular carcinoma a of hepatitis B virus 2006; PubMed Scopus Google Scholar, et B antigen and the risk of hepatocellular Engl J Med. 2002; PubMed Scopus Google Scholar, J. et risk on the of hepatitis B viral 2006; Full Text Full Text PDF PubMed Scopus Google Scholar and residents of that the and of Taiwan were to in a cancer and a total of and to with on and factors was via a by were at and on hepatitis B HBV and were using and J. et of hepatocellular carcinoma a of hepatitis B virus 2006; PubMed Scopus Google Scholar, et B antigen and the risk of hepatocellular Engl J Med. 2002; PubMed Scopus Google Scholar, J. et risk on the of hepatitis B viral 2006; Full Text Full Text PDF PubMed Scopus Google Scholar All to in and the were and by the of the of Taiwan The metabolic factors for obesity, of diabetes and and of total and The of obesity was by of mass index kg/m2) and obesity was a for and for to in the Asian S. et the of the metabolic to 2004; PubMed Scopus Google Scholar was to to and on the for the Asian index for Asian and for and 2004; Scholar A of diabetes and was from the of and were to be of on and were at study positive for or for liver cancer via was national were to with the national cancer in Taiwan to HCC cases and liver cancer identified linkage to the national cancer or from or at were from the The cancer was in in and in not all liver to the national cancer were on liver cancer cases in carriers to the HCC a all HCC cases in at of the by at 2 or for were from the of to the of HCC or were and not with HCC were on factors that may be associated with both metabolic factors and HCC in a and that were 3 All analyses were stratified by of and and persons were both and positive and were from the to of HCC cases The relative risk and 95% confidence interval were estimated by Cox proportional hazards models. and obesity obesity and of diabetes were in the with for and to whether the of HBV or HCV infections the obesity/diabetes and HCC risk in a to the joint of obesity, diabetes, and of or was estimated by the of HCC cases with metabolic factor and viral risk factor diabetes and that was to the of attributable to the combined of J PubMed Scopus Google Scholar The of from was estimated from the 95% of an on the by of attributable to the combined of J PubMed Scopus Google Scholar and the of indicating with both HBV and HCV infections were the was on of of or diabetes and both factors in with were for both and and A of metabolic obesity, and of diabetes and were among those without HBV and HCV infections to whether the was associated with increasing HCC risk in a of were by the of a the of the and other HCC risk an using a with a was HBV HCC of liver and the metabolic factors obesity, and of diabetes and were all in to the of and HCC after for the effects of other metabolic All analyses were using Scholar All analyses were without a of liver at and the the indicating that may not be for the HCC cases that of may be but at and and of metabolic factors may be to HCC. We analyses HCC cases of and the the The that HCC cases may be and with metabolic and may influence the risk be the of to the was found to have with and to the in increased HCC on to all study subjects in the the in the the was for both and were for and were for at The or of HCC risk factors in 3 is in for were were in were and the highest of diabetes and of liver HBsAg-seropositive were were in and of and the lowest of and and to be than the other 2 were for both the highest total and the highest with and A total of HCC cases were identified the The HCC was similar in 2 with HBV or HCV infection and but in the with an incidence of HCC of and of for HCC by HBV and HCV and positive and and at high or at total in and in of diabetes of at at of liver HCC in and in in a without HBV and HCV infections and or were associated with an increased risk of HCC. Extreme obesity and of diabetes were associated with an increased risk of HCC 95% CI, for ≥30 95% CI, for HBsAg-seropositive and or were associated with an increased risk of HCC. Diabetes was associated with a relative HCC risk of (95% CI, obesity were to HCC was associated with a risk of HCC 95% CI, in HBsAg-seropositive and of Incident HCC in to by HBV and HCV and positive and and positive (95% (95% (95% at high or at total for in and in of diabetes of at at in and in in a anti-HCV–seropositive subjects a HCC risk factor but not was associated with a relative HCC risk of (95% CI, and were associated with HCC but not Obesity 95% CI, for ≥30 obesity 95% CI, and of diabetes 95% CI, were associated with the risk of HCC in anti-HCV–seropositive 3 the relative HCC risk associated with metabolic factors after for other and stratified by and and obesity were were in models. were for both and of the metabolic factors were associated with HCC risk a 2-fold HCC risk observed for obesity 2.36; 95% CI, for ≥30 and diabetes 95% CI, HBsAg-seropositive of diabetes was the HCC risk factor with an of (95% CI, obesity was associated with a increased risk of HCC 95% CI, was found with increasing was associated with a risk of HCC 95% CI, anti-HCV–seropositive obesity was associated with an of (95% CI, and was associated with an increasing HCC risk in a with the highest of (95% CI, for Diabetes was associated with a increased risk of HCC in both 95% CI, 3.52; 95% CI, and were associated with HCC risk in but not of HCC in to by HBV and HCV and positive and and positive total ≥30 for obesity of diabetes of All are (95% are for in at at and high and in a All are (95% are for in at at and high and the effects of the of obesity, diabetes, and HBV and HCV infections on HCC risk, with the of HBV and HCV infections, diabetes, and The relative HCC risk was (95% CI, for the of and obesity and (95% CI, for the of and The was (95% CI, for the of and diabetes and (95% CI, for the of and all factors the relative HCC risk was high (95% CI, for HBsAg-seropositive subjects with obesity and diabetes and (95% CI, for anti-HCV–seropositive subjects with obesity and of HCC by and Extreme and of hepatitis (95% for and at high and of diabetes of and for and at high and obesity ≥30 of and for and at high and of and was HCC for and at high and of diabetes of and for and at high and obesity ≥30 of and for and at high and of and was HCC in a the of synergistic effects in an of diabetes on both 95% CI, and 95% CI, obesity HCC risk to 95% CI, but not to 95% CI, to of the were in for without HBV and HCV infections, the of metabolic factors obesity, and of diabetes and was associated with increasing HCC risk in a 95% CI, for metabolic risk The was (95% CI, the was to the and of Incident HCC in to of HBV and HCV of of for in at at and high and of metabolic factors for to those than at of metabolic factors for for in at at and high and in a analyses were to whether were associated with factors to liver and metabolic the HBV and found a of HBV and of with those for was an HBV and those with the highest HBV on were with HCC at than those not HCC All other at obesity, obesity, and of diabetes and were associated with of and of at and of HBV and of in to HCV HBV were subjects with viral obesity of diabetes of for in at and high and were subjects with viral in a for in at and high and prospective the several metabolic factors and risk of HCC was on HBV and HCV obesity and obesity ≥30 kg/m2) were independently associated with 2-fold and 4-fold increased risk of HCC among Extreme obesity was associated with 2-fold increased risk in those without HBV and HCV infections, was HBV was not associated with HCC Diabetes was associated with to increased risk of of HBV and HCV The risk was highest among those with HCV infection and lowest in HBV carriers and not in those without those without HBV and HCV infections, of metabolic factors were to for the to HCC and were We found more than 100-fold increased risk of HCC among HBV or HCV carriers with both obesity and diabetes, with those without all indicating synergistic effects of metabolic factors and hepatitis have that obesity is associated with an increased risk of H. Mellemgaard A. Lindvig K. et al.Obesity and cancer risk: a Danish record-linkage study.Eur J Cancer. 1994; 30A: 344-350Abstract Full Text PDF PubMed Scopus (398) Google Scholar, 3Wolk A. Gridley G. Svensson M. et al.A prospective study of obesity and cancer risk (Sweden).Cancer Causes Control. 2001; 12: 13-21Crossref PubMed Scopus (506) Google Scholar, 4Rapp K. Schroeder J. Klenk J. et al.Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria.Br J Cancer. 2005; 93: 1062-1067Crossref PubMed Scopus (270) Google Scholar, 5Calle E.E. Rodriguez C. Walker-Thurmond K. et al.Overweight, obesity and mortality from cancer in a prospective studied cohort of US adults.N Engl J Med. 2003; 348: 1625-1638Crossref PubMed Scopus (5870) Google Scholar, 6Samanic C. Gridley G. Chow W.H. et al.Obesity and cancer risk among white and black United States veterans.Cancer Causes Control. 2004; 15: 35-43Crossref PubMed Scopus (263) Google Scholar, 7Nair S. Mason A. Eason J. et al.Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?.Hepatology. 2002; 36: 150-155Crossref PubMed Scopus (286) Google Scholar but 2 of failed to for other metabolic factors and HCC risk factors to of H. Mellemgaard A. Lindvig K. et al.Obesity and cancer risk: a Danish record-linkage study.Eur J Cancer. 1994; 30A: 344-350Abstract Full Text PDF PubMed Scopus (398) Google Scholar, 3Wolk A. Gridley G. Svensson M. et al.A prospective study of obesity and cancer risk (Sweden).Cancer Causes Control. 2001; 12: 13-21Crossref PubMed Scopus (506) Google Scholar study observed a increased risk among the population in with the H. Mellemgaard A. Lindvig K. et al.Obesity and cancer risk: a Danish record-linkage study.Eur J Cancer. 1994; 30A: 344-350Abstract Full Text PDF PubMed Scopus (398) Google Scholar the incidence for liver cancer was (95% CI, in in A. Gridley G. Svensson M. et al.A prospective study of obesity and cancer risk (Sweden).Cancer Causes Control. 2001; 12: 13-21Crossref PubMed Scopus (506) Google Scholar of liver cancer among kg/m2) was with of in a large US E.E. Rodriguez C. Walker-Thurmond K. et al.Overweight, obesity and mortality from cancer in a prospective studied cohort of US adults.N Engl J Med. 2003; 348: 1625-1638Crossref PubMed Scopus (5870) Google Scholar et S. Mason A. Eason J. et al.Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?.Hepatology. 2002; 36: 150-155Crossref PubMed Scopus (286) Google Scholar that obesity was an independent risk factor for HCC in with 95% CI, for kg/m2) and 95% CI, but not in with HCV HBV and hepatitis. of to increased risk of HCC associated with of diabetes was with M.S. Hsieh M.S. Chiu Y.H. et al.Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection.Hepatology. 2006; 43: PubMed Scopus Google Scholar, Chow W.H. et risk of liver cancer in with diabetes PubMed Scopus Google Scholar, Gridley G. et incidence in a cohort of with diabetes in PubMed Scopus Google Scholar, C. A. et and the risk of liver J Cancer. PubMed Scopus Google Scholar, H. et of diabetes in the of hepatocellular PubMed Scopus Google Scholar, The of diabetes in hepatocellular carcinoma: a study among United States J 2001; PubMed Google Scholar, Diabetes the risk of liver and hepatocellular 2004; Full Text Full Text PDF PubMed Scopus Google Scholar, et the risk of hepatocellular carcinoma in the United a population 2005; PubMed Scopus Google Scholar, et factors for hepatocellular carcinoma: of with viral hepatitis and diabetes 2002; 36: PubMed Scopus Google Scholar, H. et and cancer risk in and 2005; PubMed Scopus Google Scholar, E.E. et a of cancer mortality in a large cohort of US J 2004; PubMed Scopus Google Scholar, S. K. et of diabetes, and viral hepatitis on risk of hepatocellular carcinoma in and in the 2004; PubMed Scopus Google Scholar, M. M. et and the risk of cancer: from a cohort study in Med. 2006; PubMed Scopus Google Scholar, H. The diabetes and hepatocellular carcinoma: a of epidemiologic 2006; Full Text Full Text PDF PubMed Scopus Google Scholar of H. The diabetes and hepatocellular carcinoma: a of epidemiologic 2006; Full Text Full Text PDF PubMed Scopus Google Scholar et the risk of hepatocellular carcinoma in the United a population 2005; PubMed Scopus Google Scholar a HCV and diabetes with an of (95% CI, for those with HCV and diabetes, with those without factor in a large study in the United study found a similar with an of (95% CI, for those with HCV and diabetes, was than the of diabetes 95% CI, and HCV 95% CI, but the not S. K. et of diabetes, and viral hepatitis on risk of hepatocellular carcinoma in and in the 2004; PubMed Scopus Google Scholar synergistic effects of diabetes and viral hepatitis with an of (95% CI, but combined hepatitis B and C a study by et M.S. Hsieh M.S. Chiu Y.H. et al.Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection.Hepatology. 2006; 43: PubMed Scopus Google Scholar found that 2 diabetes increased risk of HCC in those were HCV 95% CI, or 95% CI, The may be to HCV persons with HBV infections and to the risk from The synergistic of kg/m2) and diabetes on the risk of HCC been We found that kg/m2) not increase HCC risk to an with diabetes a synergistic in the not This is with the from that is not associated with increased risk of HCC in the with obesity ≥30 kg/m2) in to diabetes, the synergistic to in the in The of of with risk of HCC among those with HBV or HCV infections were with 2 other H. et of diabetes in the of hepatocellular PubMed Scopus Google Scholar, M. et in with hepatocellular Med. 2001; Google Scholar We HBV in a and a was observed of HBV and The and was by study conducted in Chiu Y.H. et al.A study the metabolic and hepatitis infection study J 2006; Scholar but been a on the of HBV and liver is to increase the risk of would that be associated with of the have the that may the and HCC risk study and the study by et Chiu Y.H. et al.A study the metabolic and hepatitis infection study J 2006; Scholar is associated with HBV been that in HBV may the of is the of the et hepatitis B virus of B by the of 2004; PubMed Scopus Google Scholar of B B would in of all the in the was to viral increasing of viral M. B virus is by and 2005; PubMed Scopus Google Scholar This to be with of a and viral The obesity/diabetes and HCC may be by that increase the of and to factors and risk for hepatocellular 2004; 127: Full Text Full Text PDF PubMed Scopus Google Scholar have that liver may be the factor obesity/diabetes and risk of K. K. et carcinoma in 2001; PubMed Scopus Google Scholar, et the of from to hepatocellular 2002; Full Text Full Text PDF PubMed Scopus Google Scholar been that obesity/diabetes increase the risk of HCC with liver may to M. A. et the of liver of hepatitis C and with HCV and 2001; PubMed Scopus Google Scholar the of liver been to K. K. K. et is a risk factor for hepatocellular carcinoma in with hepatitis C virus 2003; PubMed Scopus (286) Google Scholar of HCC to those at high risk to the infection of is the on of diabetes the of diabetes a without of or We diabetes from a of be of a study found and for of et and was for diabetes, and but not for 2004; Full Text Full Text PDF PubMed Scopus Google Scholar and is to that is to the or of HCC the was and more to the were to metabolic not have on and but not a metabolic factors and HCC. The of HCC cases with obesity in some stratified may the from but the all and were at and HCC cases was identified study and All risk factors were on at enrollment, and may the of the in risk and the possible in HCC risk factors over is and with HCC observed in study be to the that metabolic factors some in the of obesity and diabetes among on the HCV HCV and obesity/diabetes with risk of HCC is The mass of hepatitis B the mortality and of liver to HBV infection in et B and hepatocellular carcinoma in and PubMed Scopus Google Scholar, et hepatitis B in in the after was 2006; PubMed Scopus Google Scholar not in developed countries the United of HBV infection are and may be in to the increase in the prevalence of other risk factors hepatitis C infection and metabolic Mason incidence of hepatocellular carcinoma in the United Engl J Med. Scholar, et increase in the incidence of hepatocellular carcinoma in the United an Med. 2003; PubMed Scopus Google Scholar The of metabolic obesity and diabetes, to HCC risk differently depending on HBV and HCV infections may shed some light in preventing HCC after of hepatitis B and C. been to liver in with and liver in are associated with 2006; PubMed Scopus Google Scholar may be for of HCC. the of obesity ≥30 kg/m2) in study may to the Asian for other more are to The obesity/diabetes and HCC may not be to the but to the metabolic The S. of of for on and of the PDF

Osteoporosis is a serious health issue among aging postmenopausal women. The majority of postmenopausal women with osteoporosis have bone loss related to estrogen deficiency. The rapid bone loss results from an increase in bone turnover with an imbalance between bone resorption and bone formation. Osteoporosis can also result from excessive glucocorticoid usage, which induces bone demineralization with significant changes of spatial heterogeneities of bone at microscale, indicating potential risk of fracture. This review is a summary of current literature about the molecular mechanisms of actions, the risk factors, and treatment of estrogen deficiency related osteoporosis (EDOP) and glucocorticoid induced osteoporosis (GIOP). Estrogen binds with estrogen receptor to promote the expression of osteoprotegerin (OPG), and to suppress the action of nuclear factor-κβ ligand (RANKL), thus inhibiting osteoclast formation and bone resorptive activity. It can also activate Wnt/β-catenin signaling to increase osteogenesis, and upregulate BMP signaling to promote mesenchymal stem cell differentiation from pre-osteoblasts to osteoblasts, rather than adipocytes. The lack of estrogen will alter the expression of estrogen target genes, increasing the secretion of IL-1, IL-6, and tumor necrosis factor (TNF). On the other hand, excessive glucocorticoids interfere the canonical BMP pathway and inhibit Wnt protein production, causing mesenchymal progenitor cells to differentiate toward adipocytes rather than osteoblasts. It can also increase RANKL/OPG ratio to promote bone resorption by enhancing the maturation and activation of osteoclast. Moreover, excess glucocorticoids are associated with osteoblast and osteocyte apoptosis, resulting in declined bone formation. The main focuses of treatment for EDOP and GIOP are somewhat different. Avoiding excessive glucocorticoid use is mandatory in patients with GIOP. In contrast, appropriate estrogen supplement is deemed the primary treatment for females with EDOP of various causes. Other pharmacological treatments include bisphosphonate, teriparatide, and RANKL inhibitors. Nevertheless, more detailed actions of EDOP and GIOP along with the safety and effectiveness of medications for treating osteoporosis warrant further investigation.

The Lyon Consensus provides conclusive criteria for and against the diagnosis of gastro-oesophageal reflux disease (GERD), and adjunctive metrics that consolidate or refute GERD diagnosis when primary criteria are borderline or inconclusive. An international core and working group was assembled to evaluate research since publication of the original Lyon Consensus, and to vote on statements collaboratively developed to update criteria. The Lyon Consensus 2.0 provides a modern definition of actionable GERD, where evidence from oesophageal testing supports revising, escalating or personalising GERD management for the symptomatic patient. Symptoms that have a high versus low likelihood of relationship to reflux episodes are described. Unproven versus proven GERD define diagnostic strategies and testing options. Patients with no prior GERD evidence (unproven GERD) are studied using prolonged wireless pH monitoring or catheter-based pH or pH-monitoring off antisecretory medication, while patients with conclusive GERD evidence (proven GERD) and persisting symptoms are evaluated using pH-impedance monitoring while on optimised antisecretory therapy. The major changes from the original Lyon Consensus criteria include establishment of Los Angeles grade B oesophagitis as conclusive GERD evidence, description of metrics and thresholds to be used with prolonged wireless pH monitoring, and inclusion of parameters useful in diagnosis of refractory GERD when testing is performed on antisecretory therapy in proven GERD. Criteria that have not performed well in the diagnosis of actionable GERD have been retired. Personalisation of investigation and management to each patient's unique presentation will optimise GERD diagnosis and management.

Traditionally, peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α), a 91 kDa transcription factor, regulates lipid metabolism and long-chain fatty acid oxidation by upregulating the expression of several genes of the tricarboxylic acid cycle and the mitochondrial fatty acid oxidation pathway. In addition, PGC-1α regulates the expression of mitochondrial genes to control mitochondria DNA replication and cellular oxidative metabolism. Recently, new insights showed that several myokines such as irisin and myostatin are epigenetically regulated by PGC-1α in skeletal muscles, thereby modulating systemic energy balance, with marked expansion of mitochondrial volume density and oxidative capacity in healthy or diseased myocardia. In addition, in our studies evaluating whether PGC-1α overexpression in epicardial adipose tissue can act as a paracrine organ to improve or repair cardiac function, we found that overexpression of hepatic PGC-1α increased hepatic fatty acid oxidation and decreased triacylglycerol storage and secretion in vivo and in vitro. In this review, we discuss recent studies showing that PGC-1α may regulate mitochondrial fusion⁻fission homeostasis and affect the renal function in acute or chronic kidney injury. Furthermore, PGC-1α is an emerging protein with a biphasic role in cancer, acting both as a tumor suppressor and a tumor promoter and thus representing a new and unresolved topic for cancer biology studies. In summary, this review paper demonstrates that PGC-1α plays a central role in coordinating the gene expression of key components of mitochondrial biogenesis and as a critical metabolic regulator in many vital organs, including white and brown adipose tissue, skeletal muscle, heart, liver, and kidney.

Concerns have been growing about the veracity of psychological research. Many findings in psychological science are based on studies with insufficient statistical power and nonrepresentative samples, or may otherwise be limited to specific, ungeneralizable settings or populations. Crowdsourced research, a type of large-scale collaboration in which one or more research projects are conducted across multiple lab sites, offers a pragmatic solution to these and other current methodological challenges. The Psychological Science Accelerator (PSA) is a distributed network of laboratories designed to enable and support crowdsourced research projects. These projects can focus on novel research questions, or attempt to replicate prior research, in large, diverse samples. The PSA's mission is to accelerate the accumulation of reliable and generalizable evidence in psychological science. Here, we describe the background, structure, principles, procedures, benefits, and challenges of the PSA. In contrast to other crowdsourced research networks, the PSA is ongoing (as opposed to time-limited), efficient (in terms of re-using structures and principles for different projects), decentralized, diverse (in terms of participants and researchers), and inclusive (of proposals, contributions, and other relevant input from anyone inside or outside of the network). The PSA and other approaches to crowdsourced psychological science will advance our understanding of mental processes and behaviors by enabling rigorous research and systematically examining its generalizability.

Atherosclerosis is a chronic inflammatory disease characterized by the accumulation of lipids, smooth muscle cell proliferation, cell apoptosis, necrosis, fibrosis, and local inflammation. Immune and inflammatory responses have significant effects on every phase of atherosclerosis, and increasing evidence shows that immunity plays a more important role in atherosclerosis by tightly regulating its progression. Therefore, understanding the relationship between immune responses and the atherosclerotic microenvironment is extremely important. This article reviews existing knowledge regarding the pathogenesis of immune responses in the atherosclerotic microenvironment, and the immune mechanisms involved in atherosclerosis formation and activation.

The antioxidant and antiinflammatory effects of flavonols have been suggested to be structure-related. Results revealed that selected flavonols, including fisetin (F), kaempferol (K), morin (MO), myricetin (MY), and quercetin (Q), exhibited distinctive free radical scavenging properties against different kinds of free radicals. The H donation (DPPH bleaching) potential was Q > F approximately equals MY > MO > K, indicating that the presence of a 3',4'-catechol moiety in the B ring correlated with high activity. The 4'-OH in the B ring was suggested to be important for reducing xanthing/xanthine oxidase-generated superoxide; while an additional OH moiety on the ortho sites (3' or 5') attenuated the effect as the observed inhibitory potency was K approximately equals MO > Q > F > MY. The relative inhibitory effect for Fenton-mediated hydroxyl radical was K approximately equals MO approximately equals Q > F > MY. This result implies the involvement of 4-keto, 5-OH region in Fe++ chelating and the negative effect of pyrogallol moiety in the B ring. Similar to the inhibitory activity against a N-formyl-methionyl-leucyl-phenylalanine (f-MLP)-stimulated oxidative burst in human polymorphonuclear neutrophils (PMN), our result showed that the structural peculiarity of the di-OH in the B ring obviously rendered F, Q, and MO more potent as ROS inhibitors than MY and K, which have tri- and mono-OH in the B ring, respectively. All of the previous data indicated that the structure prerequisite to reinforce the free radical scavenging activity varies with the type of free radical. We further analyzed the effects of flavonols on nitric oxide (NO) production in endotoxin-stimulated murine macrophages, RAW264.7 cells. Results showed that all flavonols (up to 10 microM) inhibited NO production without exerting detectable cytotoxicity. F, K, and Q dose-dependently repressed iNOS mRNA expression and prostaglandin E2 (PGE2) production, in part through an attenuating NF-kappaB signaling pathway. This result indicates that flavonols, despite structural similarity, have different antioxidant and antiinflammatory effects.

BACKGROUND: Stroke is a leading cause of death and disability worldwide; however, no effective treatment currently exists. METHODS AND RESULTS: Rats receiving subcutaneous granulocyte colony-stimulating factor (G-CSF) showed less cerebral infarction, as evaluated by MRI, and improved motor performance after right middle cerebral artery ligation than vehicle-treated control rats. Subcutaneous administration of G-CSF enhanced the availability of circulating hematopoietic stem cells to the brain and their capacity for neurogenesis and angiogenesis in rats with cerebral ischemia. CONCLUSIONS: G-CSF induced increases in bone marrow cell mobilization and targeting to the brain, reducing the volume of cerebral infarction and improving neural plasticity and vascularization.

Activating transcription factor 3 (ATF3) is a stress-induced transcription factor that plays vital roles in modulating metabolism, immunity, and oncogenesis. ATF3 acts as a hub of the cellular adaptive-response network. Multiple extracellular signals, such as endoplasmic reticulum (ER) stress, cytokines, chemokines, and LPS, are connected to ATF3 induction. The function of ATF3 as a regulator of metabolism and immunity has recently sparked intense attention. In this review, we describe how ATF3 can act as both a transcriptional activator and a repressor. We then focus on the role of ATF3 and ATF3-regulated signals in modulating metabolism, immunity, and oncogenesis. The roles of ATF3 in glucose metabolism and adipose tissue regulation are also explored. Next, we summarize how ATF3 regulates immunity and maintains normal host defense. In addition, we elaborate on the roles of ATF3 as a regulator of prostate, breast, colon, lung, and liver cancers. Further understanding of how ATF3 regulates signaling pathways involved in glucose metabolism, adipocyte metabolism, immuno-responsiveness, and oncogenesis in various cancers, including prostate, breast, colon, lung, and liver cancers, is then provided. Finally, we demonstrate that ATF3 acts as a master regulator of metabolic homeostasis and, therefore, may be an appealing target for the treatment of metabolic dyshomeostasis, immune disorders, and various cancers.

Hemodynamic shear stress, the blood flow-generated frictional force acting on the vascular endothelial cells, is essential for endothelial homeostasis under normal physiological conditions. Mechanosensors on endothelial cells detect shear stress and transduce it into biochemical signals to trigger vascular adaptive responses. Among the various shear-induced signaling molecules, reactive oxygen species (ROS) and nitric oxide (NO) have been implicated in vascular homeostasis and diseases. In this review, we explore the molecular, cellular, and vascular processes arising from shear-induced signaling (mechanotransduction) with emphasis on the roles of ROS and NO, and also discuss the mechanisms that may lead to excessive vascular remodeling and thus drive pathobiologic processes responsible for atherosclerosis. Current evidence suggests that NADPH oxidase is one of main cellular sources of ROS generation in endothelial cells under flow condition. Flow patterns and magnitude of shear determine the amount of ROS produced by endothelial cells, usually an irregular flow pattern (disturbed or oscillatory) producing higher levels of ROS than a regular flow pattern (steady or pulsatile). ROS production is closely linked to NO generation and elevated levels of ROS lead to low NO bioavailability, as is often observed in endothelial cells exposed to irregular flow. The low NO bioavailability is partly caused by the reaction of ROS with NO to form peroxynitrite, a key molecule which may initiate many pro-atherogenic events. This differential production of ROS and RNS (reactive nitrogen species) under various flow patterns and conditions modulates endothelial gene expression and thus results in differential vascular responses. Moreover, ROS/RNS are able to promote specific post-translational modifications in regulatory proteins (including S-glutathionylation, S-nitrosylation and tyrosine nitration), which constitute chemical signals that are relevant in cardiovascular pathophysiology. Overall, the dynamic interplay between local hemodynamic milieu and the resulting oxidative and S-nitrosative modification of regulatory proteins is important for ensuing vascular homeostasis. Based on available evidence, it is proposed that a regular flow pattern produces lower levels of ROS and higher NO bioavailability, creating an anti-atherogenic environment. On the other hand, an irregular flow pattern results in higher levels of ROS and yet lower NO bioavailability, thus triggering pro-atherogenic effects.